---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-327828"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2025-12-22T23:59:59+00:00"
generated_at: "2026-05-16T12:23:04.215044+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BioMarin ends development of oral AATD liver disease candidate BMN 349

## Summary
- Discontinued BMN 349, an oral therapeutic for alpha-1 antitrypsin deficiency (AATD)-associated liver disease.
- Decision announced on December 19, 2025; no reason for discontinuation disclosed.
- No financial impact or pipeline replacement details provided in the filing.

## SEC filing metadata
- accession: 0001193125-25-327828
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2025-12-22T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000119312525327828/0001193125-25-327828-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000119312525327828/d45090d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-327828
- JSON: https://secwatch.observer/filing/0001193125-25-327828.json
- Plain text: https://secwatch.observer/filing/0001193125-25-327828.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.